Speed to market won't guarantee success in today's launch environment. Anticipating what prescribers, patients and payers will value is key, according to experts at EY.
Move beyond fragmented trial planning by using longitudinal patient insights to optimize protocols, improve site selection, and overcome recruitment hurdles for more predictable outcomes.
As the U.S. FDA is impacted by layoffs that threaten its oversight capabilities, the importance of robust software and manufacturing process validation has never been more critical.
Real-time release and digital quality management, powered by PAT, are driving efficiency and compliance, reshaping how manufacturers achieve speed, consistency, and competitive advantage.
Uncover how recent Canadian regulatory changes impact MDEL compliance, recall processes, and licensing requirements for medical device importers and distributors.
Discover how this patented synthetic approach to Deucravacitinib intermediates can improve yield, simplify purification, and support scalable, regulatory-aligned manufacturing.
